What’s Next for Alnylam Pharmaceuticals, Inc. (ALNY) After Forming Bullish Double Top Chart Pattern?

December 7, 2017 - By Darrin Black

Investors sentiment increased to 1.52 in 2017 Q2. Its up 0.70, from 0.82 in 2017Q1. It increased, as 24 investors sold Alnylam Pharmaceuticals, Inc. shares while 49 reduced holdings. 49 funds opened positions while 62 raised stakes. 85.40 million shares or 6.40% more from 80.26 million shares in 2017Q1 were reported.
Loring Wolcott & Coolidge Fiduciary Advsr Limited Liability Partnership Ma owns 8,275 shares for 0.01% of their portfolio. Bridger Ltd owns 759,127 shares or 3.46% of their US portfolio. Intll Gp reported 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Ecor1 Ltd Llc stated it has 10,425 shares. Glenmede Na invested in 0% or 175 shares. Bb Biotech Ag reported 2.98% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Evercore Wealth Management Llc holds 0% or 600 shares. Slate Path Capital Limited Partnership has invested 3.44% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Principal Financial Grp accumulated 15,256 shares or 0% of the stock. Parametric Portfolio Limited Liability Corp holds 0.01% or 64,943 shares in its portfolio. State Common Retirement Fund reported 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). State Street holds 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1.94 million shares. Tekla Llc has 114,966 shares for 0.34% of their portfolio. 147,194 are held by Pioneer Invest Mngmt Inc. Proshare Advsrs Ltd Limited Liability Company reported 48,505 shares stake.

The chart of Alnylam Pharmaceuticals, Inc. (ALNY) shows a double top with $139.03 target or 8.00 % above today’s $128.73 share price. The 5 months chart pattern indicates low risk for the $12.77B company. It was reported on Dec, 7 by Finviz.com. If the $139.03 price target is reached, the company will be worth $1.02B more. Double tops are rare but powerful chart patterns.

The stock increased 3.34% or $4.16 during the last trading session, reaching $128.73. About 754,726 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since December 7, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.36 EPS, down 3.03 % or $0.04 from last year’s $-1.32 per share. After $-1.34 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.49 % negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 84 analyst reports since August 7, 2015 according to SRatingsIntel. JMP Securities maintained it with “Outperform” rating and $144 target in Friday, August 28 report. Needham maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Monday, June 26. Needham has “Buy” rating and $9800 target. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Cowen & Co on Thursday, September 21. The firm has “Buy” rating given on Monday, June 12 by Chardan Capital Markets. The rating was maintained by Cowen & Co with “Buy” on Tuesday, July 11. The firm earned “Buy” rating on Wednesday, September 20 by Piper Jaffray. The firm has “Outperform” rating by Credit Suisse given on Wednesday, January 20. Needham maintained it with “Buy” rating and $137 target in Thursday, October 6 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Monday, December 19 by Chardan Capital Markets. As per Thursday, November 2, the company rating was maintained by Piper Jaffray.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Alnylam Pharmaceuticals, Inc.’s Pipeline Progresses, Approval Next” on November 15, 2017, also Businesswire.com with their article: “Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock …” published on November 16, 2017, Businesswire.com published: “Alnylam Pharmaceuticals Announces Proposed Public Offering of $675000000 of …” on November 13, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Nasdaq.com and their article: “Commit To Buy Alnylam Pharmaceuticals At $70, Earn 11.4% Using Options” published on November 28, 2017 as well as Seekingalpha.com‘s news article titled: “Alnylam Sets Its Eyes On The Finish Line” with publication date: November 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.